Inhibitors of the interferon response enhance virus replication in vitro

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Stewart, Claire E ^a   Rall, Richard E ^a   Adamson, Catherine S ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; BX 795; INTERFERON; LIVE VACCINE; MRT 67307; MRT 68844; RUXOLITINIB; TOFACITINIB; UNCLASSIFIED DRUG; CULTURE MEDIUM; GREEN FLUORESCENT PROTEIN; PYRAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA; MEASLES; MUMPS; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIROGENESIS; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHLOROCEBUS AETHIOPS; CULTURE MEDIUM; CULTURE TECHNIQUE; DOG; DRUG EFFECTS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MDCK CELL LINE; MEASLES VIRUS; METABOLISM; MOUSE; MUMPS VIRUS; ORTHOMYXOVIRIDAE; PHYSIOLOGY; PIG; PROCEDURES; RABBIT; TUMOR CELL LINE; VERO CELL LINE;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CULTURE MEDIA; DOGS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERONS; MADIN DARBY CANINE KIDNEY CELLS; MEASLES VIRUS; MICE; MUMPS VIRUS; ORTHOMYXOVIRIDAE; PYRAZOLES; RABBITS; RESPIRATORY SYNCYTIAL VIRUSES; SWINE; VERO CELLS; VIRUS REPLICATION;

EID: 84911493910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112014     Document Type: Article

References (37)

1. Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
2. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, et al. (2000) Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A 97: 4309-4314.
3. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742-1753.
4. Mossler C, Groiss F, Wolzt M, Wolschek M, Seipelt J, et al. (2013) Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 31: 6194-6200.
5. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, et al. (2008) Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82: 2681-2691.
6. Brennan B, Welch SR, McLees A, Elliott RM (2011) Creation of a recombinant Rift Valley fever virus with a two-segmented genome. J Virol 85: 10310-10318.
7. Teng MN, Collins PL (1999) Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol 73: 466-473.
8. Luongo C, Winter CC, Collins PL, Buchholz UJ (2013) Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 87: 1985-1996.
9. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
10. Naik S, Russell SJ (2009) Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 9: 1163-1176.
11. Young DF, Andrejeva L, Livingstone A, Goodbourn S, Lamb RA, et al. (2003) Virus replication in engineered human cells that do not respond to interferons. J Virol 77: 2174-2181.
12. Desmyter J, Melnick JL, Rawls WE (1968) Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 2: 955-961.
13. Mosca JD, Pitha PM (1986) Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol 6: 2279-2283.
14. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE, et al. (2006) The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 80: 11723-11732.
15. House C, House JA (1989) Evaluation of techniques to demonstrate foot-andmouth disease virus in bovine tongue epithelium: comparison of the sensitivity of cattle, mice, primary cell cultures, cryopreserved cell cultures and established cell lines. Vet Microbiol 20: 99-109.
16. Chen S, Short JA, Young DF, Killip MJ, Schneider M, et al. (2010) Heterocellular induction of interferon by negative-sense RNA viruses. Virology 407: 247-255.
17. Killip MJ, Young DF, Gatherer D, Ross CS, Short JA, et al. (2013) Deep sequencing analysis of defective genomes of parainfluenza virus 5 and their role in interferon induction. J Virol 87: 4798-4807.
18. Bridgen A, Weber F, Fazakerley JK, Elliott RM (2001) Bunyamwera bunyavirus nonstructural protein NSs is a nonessential gene product that contributes to viral pathogenesis. Proc Natl Acad Sci U S A 98: 664-669.
19. Teng MN, Whitehead SS, Bermingham A, St Claire M, Elkins WR, et al. (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74: 9317-9321.
20. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, et al. (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324-330.
21. He B, Paterson RG, Stock N, Durbin JE, Durbin RK, et al. (2002) Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteinerich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303: 15-32.
22. Matrosovich M, Matrosovich T, Garten W, Klenk HD (2006) New low-viscosity overlay medium for viral plaque assays. Virol J 3: 63.
23. Clark K, Plater L, Peggie M, Cohen P (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 284: 14136-14146.
24. Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, et al. (2011) Novel cross-talk within the IKK family controls innate immunity. Biochem J 434: 93-104.
25. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, et al. (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)a-mino]- 5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 312: 373-381.
26. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, et al. (2009) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23: 1441-1445.
27. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
28. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
29. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
30. Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227: 168-170.
31. Kwilas S, Liesman RM, Zhang L, Walsh E, Pickles RJ, et al. (2009) Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol 83: 10710-10718.
32. Enders JF, Levens JH, Stokes J Jr, Maris EP, Berenberg W (1946) Attenuation of virulence with retention of antigenicity of mumps virus after passage in the embryonated egg. J Immunol 54: 283-291.
33. Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr, Whitman JE Jr, et al. (1968) Development and evaluation of the Moraten measles virus vaccine. Jama 206: 587-590.
34. Bankamp B, Takeda M, Zhang Y, Xu W, Rota PA (2011) Genetic characterization of measles vaccine strains. J Infect Dis 204 Suppl 1: S533-548.
35. Young DF, Galiano MC, Lemon K, Chen YH, Andrejeva J, et al. (2009) Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonist. J Gen Virol 90: 2731-2738.
36. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW (2013) Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther 20: 582-589.
37. Vaddi K, Sarlis NJ, Gupta V (2012) Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother 13: 2397-2407.